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Abstract
Intellectual disability (ID) is a neurodevelopmental condition that affects ~1% of the world population. In total 5−10% of ID
cases are due to variants in genes located on the X chromosome. Recently, variants in OGT have been shown to co-segregate
with X-linked intellectual disability (XLID) in multiple families. OGT encodes O-GlcNAc transferase (OGT), an essential
enzyme that catalyses O-linked glycosylation with β-N-acetylglucosamine (O-GlcNAc) on serine/threonine residues of
thousands of nuclear and cytosolic proteins. In this review, we compile the work from the last few years that clearly
delineates a new syndromic form of ID, which we propose to classify as a novel Congenital Disorder of Glycosylation
(OGT-CDG). We discuss potential hypotheses for the underpinning molecular mechanism(s) that provide impetus for future
research studies geared towards informed interventions.
Introduction
Intellectual disability (ID) is an early-onset neurodevelop-
mental condition characterised by deﬁcits in intelligence
(IQ < 70) and concomitant defects in adaptive behaviour
[1, 2]. An estimated 0.5−3% of the population in the
developed world is affected by the condition [3–6]. Although
ID can occur in isolation (nonsyndromic ID), it is often
accompanied by a broad spectrum of other mental or physical
limitations (syndromic ID). Causes underlying ID are het-
erogeneous [7–9]; and the aetiology of ~30% of ID cases is
unknown [9]. Monogenic causes account for 40% of all ID
with a genetic component, yet, one of over 800 genes can be
involved. Since X-linked genes were shown to be expressed
more abundantly in the brain than in any other tissue [10], the
X chromosome has a disproportionately higher number of
genes implicated in mental ability compared with other
chromosomes [11, 12]. Indeed, aberrations in at least 140
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genes located on the X chromosome were found to cause
X-linked intellectual disability (XLID) [13–16], although
several candidate genes remain controversial [13].
Human O-GlcNAc transferase (OGT), located on the X
chromosome (Xq13.1), encodes a 110 kDa protein [17, 18]
that is highly conserved from Caenorhabditis elegans to
Homo sapiens [19]. OGT catalyses O-linked glycosylation
of nuclear, cytosolic, and mitochondrial proteins with β-N-
acetylglucosamine (O-GlcNAc), which is an essential pro-
tein serine/threonine modiﬁcation in vertebrata [19–21].
Attachment and removal of the O-GlcNAc moiety on
mammalian nuclear and cytoplasmic proteins is performed
by only two enzymes: OGT and O-GlcNAcase (OGA),
respectively (Fig. 3). O-GlcNAcylation is thought to be
involved in key cellular processes such as gene regulation
and expression [22–24], metabolic activity [25], and cell-
cycle regulation [26]. Changes in O-GlcNAc homoeostasis
have been linked to severe developmental problems and
neurodegenerative diseases [27–33].
OGT is a multi-domain protein characterised by a catalytic
domain (CD) at the C-terminus and an N-terminal tetra-
tricopeptide repeat domain (TPR) that is involved in substrate
recognition and protein–protein interactions (Fig. 1) [34–36].
OGT is essential for mouse embryonic stem cell (mESC) and
somatic cell survival [19, 37], whereas ablation of OGT is
embryonic lethal in mice [19], zebraﬁsh [38], and Drosophila
[39]. Sxc, the gene encoding Drosophila OGT (DmOGT)
belongs to the family of homeotic genes, the Polycomb
group, which regulate segmentation during development
[39–41]. Sxc loss of function leads to a super sex combs
phenotype in Drosophila [39] and death in the adult pharate
stage. Interestingly, in addition to its catalytic function, OGT
promotes the proteolytic processing and activation of a
chromatin-bound transcriptional co-regulator host cell factor
1 (HCF1) [42, 43].
Over the past 4 years, six reports have described
the discovery of the ﬁrst OGT variants causal for XLID
[29–33, 44, 45] (OGT-XLID variants), suggesting a possi-
ble link between the O-GlcNAc system and neurodevelop-
ment. Here, we ﬁrst present common clinical features of
these patients suggestive of a syndromic form of XLID
(Fig. 2 and Table 1). We then discuss potential, and not
mutually exclusive, hypotheses that could explain the cel-
lular mechanisms underpinning neuropathogenesis (Fig. 1).
Clinical features of patients with OGT-XLID variants
Thirteen affected individuals from seven families presenting
with previously unclassiﬁed ID and developmental delay
were subjected to genetic testing and found to carry non-
synonymous variants in the OGT gene (NM_181672.2,
GenBank) located on the X chromosome (Table 1). Three
patients carried de novo variants resulting in single-amino
acid variants in the CD of OGT, one patient with
NM_181672.2:c.1942A>T p.(Asn648Tyr) [33, 46] and two
patients with NM_181672.2:c.1701=/T>A p.(Asn567Lys)
Le254Phe
Ala259Thr
Arg284Pro
Ala319Thr Glu339Gly
Asn567LysAsn648Tyr
Le254Phe
Ala259Thr
Arg284Pro
Ala319Thr
Glu339Gly
Asn567Lys
Asn648Tyr
Fig. 1 3D crystal structure of
human OGT with mapped
variants. Model for the full-
length human OGT produced by
superposition of crystallographic
models for the human OGT
catalytic core (Protein Data
Bank code 5C1D) and TPR
domain (Protein Data Bank code
1W3B). Green region represents
the TPR, yellow region
represents the CD, and purple
highlighted residues represent
variants found in OGT-XLID
patients.
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[32, 47], while all others carried inherited variants in the
TPR domain of OGT NM_181672.2:c.762G>C p.(Leu254-
Phe) [30], NM_181672.2:c.775G>A p.(Ala259Thr) [31],
NM_181672.2:c.851G>C p.(Arg284Pro) [29], NM_181672.
2:c.955G>A p.(Ala319Thr) [44], NM_181672.2:c.1016A>
G p.(Glu339Gly) [31], (Fig. 3). Four of the identiﬁed var-
iants are found in multiple probands from the same families:
three males with the c.762G>C p.(Leu254Phe) variant, three
brothers with the c.955G>A p.(Ala319Thr) variant, two
brothers with the c.1016A>G p.(Glu339Gly) variant, female
twins with the c.1701=/T>A p.(Asn567Lys) variant and
a male with c.1942A>T p.(Asn648Tyr) variant. All the
patients carrying OGT variants suffer from decreased intel-
lectual ability with IQ scores well below 70. In addition, all
patients show mental and physical developmental delay,
including intrauterine growth retardation, low birth weight,
short stature, drooling, and delayed and/or very restricted
language skills.
Brain anomalies were a commonly observed clinical
observation among XLID patients with an aberrant OGT
(Table 1). Three probands with different OGT variants pre-
sent with microcephaly, while megacisterna magna was
found in two patients. Additional anatomical brain abnorm-
alities reported among OGT-XLID patients include thin
corpus callosum, periventricular leukomalacia, brain atrophy,
and cerebral palsy spastic diplegia.
Patients with OGT-XLID variants show a distinct physical
dysmorphology (summarised in Table 1 and Fig. 2) sugges-
tive of a syndromic form of XLID. Clinodactyly of the ﬁfth
ﬁnger was found in ﬁve cases, while syndactyly and cone-
shaped epiphyses of T2–T5 were reported in one patient
(Table 1). Fingers are noted as long and thin in a subset of
patients. In addition, some patients have frontal hair upsweeps
and high-arched palates. Dysmorphic facial features identiﬁed
in probands with OGT-XLID variants include triangular,
dolichocephalic head with broad and high forehead, full lips,
broad nasal root, low set and big ears, full or long philtrum,
and hypertelorism (Fig. 2). In patients with detailed clinical
description, coarse facial features with drooling are often
described, which resembles storage disorders.
Hypotonia, epilepsy/seizures, and genital defects were
observed among many of the patients carrying OGT-XLID
variants. Six patients were reported to have behavioural
problems and two patients presented with sleep abnormal-
ities. Furthermore, some patients display visual and hearing
impairment, and suffer from recurrent otitis. Importantly,
long ﬁngers and eye abnormalities, including myopia and
astigmatism, were observed in a high proportion of patients
a) c.762G>C p.(Leu254Phe) b) c.851G>C p.(Arg284Pro) 
c) c.955G>A p.(Ala319Thr) d) c.1016A>G p.(Glu339Gly)
f) c.1701=/T>A p.(Asp567Lys)e) c.1942A>T p.(Asp648Tyr)
Fig. 2 Facial photographs of
patients with variants in OGT.
a Three affected males from a
family with c.762G>C p.
(Leu254Phe) variant [30]. b One
affected male with c.851G>C
p.(Arg284Pro) variant [29].
c One affected male with
c.955G>A p.(Ala319Thr)
variant [44]. d Two affected
males in family with c.1016A>G
p.(Glu339Gly) variant [31].
e Affected male with
c.1942A>T p.(Asn648Tyr)
variant [33]. f Affected female
twins with c.1701=/T>A
p.(Asn567Lys) OGT variant
[32]. Note the wide mouth, thin
upper lip, full lower lip, and
smooth philtrum in most of the
males. The female twins have a
full lower lip and twin 2 has a
wide mouth.
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with OGT-XLID variants, while these characteristics are
not common in XLID syndromes. Patients are negative
for glycosylated transferrin test results, excluding most
N-linked congenital disorders of glycosylation (CDGs).
In conclusion, several clinical features, namely brain
abnormalities, general developmental delay, clinodactyly
and long ﬁngers, eye abnormalities, and coarse facial fea-
tures with high forehead and triangular face are shared
among the majority of patients with OGT-XLID variants.
Based on these common symptoms, we propose that this
constitutes a novel syndrome.
Potential mechanism(s) of disease
Hypo O-GlcNAcylation
OGT and O-GlcNAcylated proteins are present in both post-
and presynaptic terminals, and O-GlcNAc modiﬁed proteins
account for 40% of all neuronal proteins and 19% of synap-
tosome proteins [48]. Perhaps the most obvious hypothesis is
that the OGT-XLID variants possess reduced catalytic activity
affecting neurodevelopmental pathways (Fig. 2). However,
several of the recombinant OGT variants do demonstrate
catalytic activity towards both peptide and protein substrates
in vitro [29–32] (Table 2). Subsequent analyses in patient-
derived or CRISPR/Cas9 engineered cell lines revealed only
minor reductions, if any, in global O-GlcNAc levels, with the
exception of the c.1942A>T p.(Asn648Tyr) OGT variant that
displayed a signiﬁcant reduction in modiﬁed proteins in
mESC [33] (Table 2). However, the methods used, primarily
western blotting of 1-D SDS-PAGE gels with various pan-O-
GlcNAc antibodies, are known to have drawbacks including
limited resolution. A much more sensitive approach would be
to use combined enrichment and tandem mass tag spectro-
metry approaches to deﬁne the O-GlcNAcome [49–53] and
quantitatively compare wild-type and OGT-XLID mutant cell
lines and/or tissues. Therefore, while not currently supported
by existing ﬁndings, this hypothesis for OGT variants’ cata-
lytic activities being impaired for speciﬁc substrates cannot be
formally excluded.
Table 1 Clinical ﬁndings observed in OGT-XLID.
OGT variant (reference
sequence NM_181672.2)
c.762G>C
p. (Leu254Phe)
c.775G>A
p. (Ala259Thr)
c.851G>C
p. (Arg284Pro)
c.955G>A
p. (Ala319Thr)
c.1016A>G
p. (Glu339Gly)
c.1942A>T
p. (Asn648Tyr)
c.1701/T>A
p. (Asn567Lys)
Total
TPR domain variants Catalytic domain variants
Reference Vaidyanathan
et al. [30]
Selvan et al.
[31]
Willems et al.
[29]
Bouazzi et al.
[44]
Selvan et al.
[31]
Pravata et al.
[32]
Pravata et al.
[33]
Number of individuals 3 males 1 male 1 male 3 males 2 males 1 male 2 females 13
Behavioural problems 0/3 1/1 1/1 2/3 2/2 1/1 NA 7/11
Hypotonia NA NA NA NA 1/2 1/1 2/2 4/5
Drooling NA NA NA NA NA 1/1 NA 1/13
Genital/reproductive
abnormalities
2/3 0/1 1/1 NA 0/2 0/1 NA 3/8
Epilepsy/seizures/dystonia 0/3 1/1 NA 0/3 0/2 0/1 NA 1/10
Eye abnormalities 3/3 1/1 1/1 2/3 0/2 1/1 2/2 10/13
Ear abnormalities/hearing
impairment
0/3 1/1 0/1 1/3 2/2 1/1 NA 5/11
Brain abnormalities NA 1/1 1/1 0/3 0/2 1/1 2/2 5/10
Microcephaly 1/3 1/1 1/1 0/3 0/2 0/1 0/2 3/13
Thin corpus callosum NA 1/1 NA 0/3 NA 0/1 NA 1/5
Dysmorphic features 3/3 1/1 1/1 2/3 2/2 1/1 2/2 12/13
Dolichocephalic head NA NA NA 2/3 2/2 0/1 NA 4/6
Frontal hair upsweep 2/3 NA NA 2/3 0/2 0/1 NA 4/9
Full lips 1/3 NA 1/1 NA 0/2 1/1 NA 3/7
Full/long philtrum 1/3 NA NA 2/3 2/2 0/1 NA 5/9
Broad nasal root NA NA 1/1 NA 1/2 1/1 NA 3/4
Clinodactyly 3/3 0/1 1/1 1/3 1/2 Syndactyly 2/2 9/13
Long thin ﬁngers NA NA 1/1 3/3 0/2 1/1 NA 5/7
Developmental delay 3/3 1/1 1/1 3/3 2/2 1/1 2/2 13/13
Low birth weight NA 1/1 NA 2/3 1/2 0/1 2/2 6/9
Short stature 3/3 1/1 NA 2/3 0/2 0/1 NA 6/10
Language delay/problems NA NA NA 3/3 2/2 1/1 2/2 8/8
IQ IQ 49, IQ
61, IQ 58
moderate ID WPPSI-III-NL,
score 2;9
IQ 40, IQ
35, IQ 30
Mild-to-
moderate ID
Moderate-to-
severe ID
ID 13/13
NA indicates cases where no information was available. Numbers indicate number of affected patients over number of patients examined per
variant and for the phenotype. Information relating to male patients is highlighted in italics. Information relating to female patients is underlined.
Frequently observed phenotypes are highlighted in bold.
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OGA levels
With the only exception of human embryonic stem cells
[31], cell lines carrying the OGT-XLID variants appeared to
have signiﬁcantly reduced levels of OGA at the protein
[29, 30, 32, 33] and mRNA [30, 32] level (Fig. 1 and
Table 2). Thus, perhaps OGT, OGA, and O-GlcNAc levels
operate in transcriptional and/or post-translational feedback
mechanisms to maintain O-GlcNAc homoeostasis. Indeed,
it has been shown that OGA is capable of upregulating OGT
gene expression through activation of the transcription
factor CCAAT/enhancer-binding protein β (C/EBP-β) [54].
Moreover, inhibition of OGA has been demonstrated to
increase OGA gene expression, showing that increased
O-GlcNAcylation promotes the transcription of OGA itself
in different cell lines [54]. Thus, variants in OGT may
lead to reduction of OGA protein/transcript to maintain
O-GlcNAc homoeostasis. This also opens the possibility
that the OGT-XLID phenotypes are caused by reduced
expression of a functional OGA. Indeed, OGA has recently
been implicated in neurodevelopmental disease. A recent
genome-wide association meta-analysis identiﬁed OGA
intronic variants as linked to nervous system development
and, more broadly, to intelligence [55]. Furthermore,
knocking down OGA in mouse brain leads to microcephaly,
hypotonia, and developmental delay [56], suggesting a
possible link between OGT-XLID variants and perturba-
tions of OGA levels.
HCF1 misprocessing
The second activity of OGT is the promotion of the cleavage
of HCF1 [42] (Fig. 1). HCF1 is potent regulator of embryonic
neural development and has also been identiﬁed as an XLID
gene [57]. Variants of HCFC1 lead to various neurological
phenotypes, which include ID. Thus, a possible hypothesis
behind the OGT-related XLID phenotypes is that HCF1 is
misprocessed. To explore this link, HCF1 processing activity
of OGT and the XLID variants has been explored in vitro
using recombinant mutant enzymes (Table 2). Changes in
HCF1 processing were observed for the c.851G>C
p.(Arg284Pro) and c.1701=/T>A p.(Asn567Lys) variants
[29, 32]. For the c.1701=/T>A p.(Asn567Lys) variant, which
shows the largest effects in vitro, subsequent analysis of
HCF1 processing has been carried out in mESC. This
approach revealed a direct link between an OGT-XLID var-
iant and misprocessing of HCF1 in cultured cells. Further-
more, RT-qPCR analysis of GABPA, a known target of HCF1
and known to mediate synapse-speciﬁc gene expression [58],
showed increased levels of the gene [32].
Taken together, these results suggest that there may be an
association between OGT-XLID variants and HCF1 pro-
cessing. However, while c.1701=/T>A p.(Asn567Lys)
appears to affect HCF1 processing, current data across all
variants suggest that HCF1 misprocessing is unlikely to be
the general mechanism by which OGT variants lead to the
observed XLID phenotypes (Table 2).
Fig. 3 OGT may mediate XLID pathology via alterations in the O-
GlcNAcome, HCF1 processing, or misfolding. OGT catalyses the
transfer of O-GlcNAc moiety onto Ser/Thr residues of acceptor sub-
strates. This modiﬁcation is removed by the OGA enzyme. Variants in
the OGT gene which lead to amino acid substitutions in the OGT
protein may mediate the XLID pathophysiology via (1) downstream
effect on the O-GlcNAc proteome, (2) alterations in OGA levels, (3)
incorrect processing of the HCF1 transcriptional coregulatory HCF1
which is also encoded by an XLID-associated gene (HCFC1), (4)
misfolding of OGT possibly leading to misfolded OGT aggregation,
and (5) perturbation in OGT interactome.
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OGT misfolding
Missense variants in many genes lead to protein misfolding
and aggregation, which is particularly toxic to terminally
differentiated neurons that entirely rely on proteolytic pro-
cessing to resolve such aggregates. Therefore another
potential mechanism underlying the OGT-related XLID
phenotype is that the OGT-XLID variants are unstable
and/or aggregate. In support of this hypothesis, detailed
crystallographic structural analysis of the c.762G>C
p.(Leu254Phe) variant revealed that the larger phenylala-
nine does not ﬁt the space occupied by the smaller leucine
in the wild-type structure, leading to dramatic conforma-
tional shifts of up to 15 Å [59]. Atomistic molecular
dynamics simulations demonstrated that the amino acid
change destabilises the interface between two TPR repeats
in the N-terminal domain, increasing the conformational
space accessible to OGT. Similarly, the c.1942A>T
p.(Asn648Tyr) crystal structure reveals that variant of the
conserved asparagine to a tyrosine creates an additional
pi–pi stacking interaction within the globular CD. This
interaction ampliﬁes the inherent ﬂexibility of the surface
exposed loop connecting the two interacting tyrosine resi-
dues, which is otherwise rigid [33]. Furthermore, in vitro
determination of protein unfolding melting curves demon-
strated that all the XLID variants but the c.1942A>T
p.(Asn648Tyr) destabilised OGT (Table 2). Collectively,
these data show that OGT-XLID variants are destabilised.
However, western blotting analysis of OGT protein levels in
the majority of cell lines carrying the XLID variants showed
unaltered OGT protein levels (Table 2). In summary,
despite reductions in the thermal stability of OGT-XLID
mutants and some structural evidence for misfolding, there
is no evidence yet of formation of toxic aggregates in cul-
tured mammalian cells.
OGT interactome
A ﬁfth hypothesis arises from the localisation of several
OGT-XLID variants to the TPR domain of OGT. This builds
on the prevalent model in the ﬁeld to reconcile that there are
thousands of substrates but only one OGT and thus, OGT is
proposed to be regulated by protein interactors that target it
to substrates. Since the TPR domain is known to be essential
for selection of substrates and their glycosylation [60], it is
possible that the TPR XLID variants of OGT lead to
impaired recognition and binding to substrates, likely in a
tissue-speciﬁc manner. Single-amino acid substitutions in
TPRs have been documented to interrupt highly speciﬁc
protein–protein interactions [61]; therefore, it is possible that
TPR variants in OGT interrupt speciﬁc substrate and/or
adaptor protein interactions. The loss of interaction with
adaptor proteins and/or glycosylation of the target substrateTa
bl
e
2
B
io
ch
em
ic
al
ch
ar
ac
te
ri
st
ic
s
of
O
G
T
va
ri
an
ts
fo
un
d
in
X
L
ID
pa
tie
nt
s.
O
G
T
va
ri
an
t
c.
76
2G
>
C
p.
(L
eu
25
4P
he
)
c.
77
5G
>
A
p.
(A
la
25
9T
hr
)
c.
85
1G
>
C
p.
(A
rg
28
4P
ro
)
c.
95
5G
>
A
p.
(A
la
31
9T
hr
)
c.
10
16
A
>
G
p.
(G
lu
33
9G
ly
)
c.
19
42
A
>
T
p.
(A
sn
64
8T
yr
)
c.
17
01
/T
>
A
p.
(A
sn
56
7L
ys
)
T
ot
al
T
P
R
do
m
ai
n
va
ri
an
ts
C
at
al
yt
ic
do
m
ai
n
va
ri
an
ts
R
ef
er
en
ce
V
ai
dy
an
at
ha
n
et
al
.
[3
0]
▲
G
un
do
gd
u
et
al
.
[5
9]
□
S
el
va
n
et
al
.
[3
1]
●
S
el
va
n
et
al
.
[3
1]
W
ill
em
s
et
al
.[
29
]
*
S
el
va
n
et
al
.
[3
1]
●
S
el
va
n
et
al
.
[3
1]
S
el
va
n
et
al
.
[3
1]
P
ra
va
ta
et
al
.
[3
2]
P
ra
va
ta
et
al
.
[3
3]
D
ec
re
as
ed
O
G
T
st
ab
ili
ty
Y
es
▲
,□
,●
Y
es
Y
es
*
Y
es
Y
es
N
o
Y
es
6/
7
D
ec
re
as
ed
O
G
T
ac
tiv
ity
N
o▲
,●
,
ye
s□
N
o
Y
es
*,
no
●
N
o
N
o
Y
es
Y
es
2–
3/
7
D
ec
re
as
ed
O
G
T
le
ve
l
Y
es
▲
,
no
●
N
o
Y
es
*,
no
●
N
A
N
o
N
o
N
o
0–
2/
6
D
ec
re
as
ed
O
G
A
le
ve
l
Y
es
▲
,
no
●
N
o
Y
es
*,
no
●
N
A
N
o
Y
es
Y
es
2–
4/
6
D
ec
re
as
ed
O
-G
lc
N
A
cy
la
tio
n
le
ve
l
N
o▲
,●
N
o
N
o*
,●
N
A
N
o
Y
es
N
o
1–
2/
6
A
ff
ec
te
d
H
C
F
1
pr
oc
es
si
ng
N
o▲
,●
N
o
Y
es
*,
●
N
o
N
o
N
A
Y
es
2/
6
N
A
in
di
ca
te
s
ca
se
s
w
he
re
no
in
fo
rm
at
io
n
w
as
av
ai
la
bl
e.
P
ub
lic
at
io
ns
w
hi
ch
pr
ov
id
ed
bi
oc
he
m
ic
al
an
al
ys
is
of
th
e
in
di
vi
du
al
va
ri
an
ts
ar
e
lis
te
d
in
th
e
se
co
nd
ro
w
.S
ym
bo
ls
in
di
ca
te
th
e
pu
bl
ic
at
io
n
in
w
hi
ch
ob
se
rv
at
io
ns
w
er
e
re
po
rt
ed
if
m
ul
tip
le
re
fe
re
nc
es
ar
e
av
ai
la
bl
e.
F
re
qu
en
tly
ob
se
rv
ed
ph
en
ot
yp
es
ar
e
hi
gh
lig
ht
ed
in
bo
ld
.
V. M. Pravata et al.
could lead to functional consequences for the substrate
protein that have yet to be deﬁned. However, the presence of
CD variants in OGT that lead to XLID with similar phe-
notypes complicate this hypothesis. In order to address this,
the OGT interactome in appropriate tissues and/or differ-
entiated cell lines must ﬁrst be deﬁned. Comparisons can
then be made between the wild-type and XLID variant OGT
interactomes to identify differential interactors and evaluate
impact on a subset of adaptor proteins and their binding
partners that could easily be overlooked via western blotting
of whole cell extracts. Deﬁning the O-GlcNAcome and O-
GlcNAc cycling rates, will be essential to evaluate the role
of catalytic OGT variants in this hypothesis.
Discussion
Pathogenic variants in OGT are mainly associated with
intellectual and developmental disability, microcephaly, eye
abormalities, and coarse facial features with high, broad
forehead, and triangular face. This might be an X-linked
CDG like ALG13-CDG, ATP6AP1-CDG, ATP6AP2-
CDG, MAGT1-CDG, PIGA-CDG, SLC35A2-CDG, SSR4-
CDG, and TRAPPC2-CDG [62]. Therefore, we term this
syndrome OGT-CDG.
This review has discussed a number of hypotheses, some
of which have been partially tested, as to the biological
mechanisms underpinning the patient phenotypes (Fig. 3).
The hypotheses of decreased OGT activity as a glycosyl-
transferase or protease are not supported as a common
mechanism by currently existing data on multiple variants.
The contribution of decreased OGT/OGA levels due to
decreased OGT stability, the possibility for aberrant interac-
tions between OGT-CDG variants and target substrates, and
alterations in O-GlcNAc cycling rates are compelling
hypotheses that still need to be explored. To achieve this
goal, new approaches to examining the OGT interactome, the
O-GlcNAcome, and the dynamics of the O-GlcNAc mod-
iﬁcation must be developed. Generation and characterisation
of CRISPR/Cas9 engineered stem cells and model organisms
will signiﬁcantly contribute to the elucidating of the biolo-
gical processes that underlie the OGT-CDG pathology. First
attempts have been made with the generation of human and
mouse ES cells and a ﬂy model of the c.1701=/T>A
p.(Asn567Lys) variant, although further work is required
including vertebrate models of the disorder. Indeed, such
disease models and in-depth the understanding of the disease
mechanism they offer will be instrumental in devising a
potential therapeutic intervention strategy.
Many studies have reported dietary interventions with
monosaccharides such as galactose, fucose, or mannose as
successful therapies used in patients suffering from CDGs
[63]. These are aimed at increasing intracellular
concentrations of metabolites speciﬁc for each subtype and,
interestingly, were successfully used in CAD-CDG with
uridine supplementation [64], SLC39A8-CDG with man-
ganese [65], and TMEM165-CDG with galactose [66]. A
similar approach could be considered for OGT variants.
Indeed, it has been observed that supplementation of cell
culture media with glucosamine (GlcN), bypassing the
feedback inhibition of the enzyme GFAT, leads to elevated
levels of UDP-GlcNAc, which are known to regulate OGT
activity [18, 67]. For the patient with the c.1942A>T
p.(Asn648Tyr) variant, GlcN supplementation is being
explored with some positive effects [33]. Another interest-
ing approach could be the use of OGA inhibitors. Indeed,
many OGA inhibitors have been described and showed to
be cell permeable [68–70], suggesting this may be a pos-
sible future therapeutic approach.
A suitable diagnostic test has to be devised to detect OGT-
XLID in patients. A commonly used CDG diagnostic test is
isoelectrofocusing of serum transferrin. Since transferrin is
only N-glycosylated, it detects only N-glycosylation dis-
orders associated with sialic acid deﬁciency and thus not
OGT-CDG. Since patient-derived cells show reduced OGA,
we propose western blotting for OGA protein levels as a
rapid initial diagnostic test for OGT-CDG.
In conclusion, more than 30 years after the discovery of
the O-GlcNAc modiﬁcation and 20 years after the cloning
of OGT [17, 18], the O-GlcNAc system has now been
linked directly to a congenital disorder and we can take
advantage of the huge strides made in understanding this
modiﬁcation in other settings [71] in order to uncover its
role in this syndromic form of OGT-CDG.
Funding This work was funded by a Wellcome Trust Senior Research
Fellowship (WT087590MA) to DMFvA.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
An intellectual disability syndrome with single-nucleotide variants in O-GlcNAc transferase
References
1. Schalock RL, Brothwick-Duffy SA, Bradley VJ, Buntinx WHE,
Coulter DL, Craig EM, et al. Intellectual disability: deﬁnition,
classiﬁcation, and systems of supports user’s guide. 8403 Coles-
ville Road, Suite 900, Silver Spring, MD: American Associacion
on Intellectual and Developmental Disabilities; 2010.
2. Tassé MJ, Luckasson R, Schalock RL. The relation between
intellectual functioning and adaptive behavior in the diagnosis of
intellectual disability. Intellect Dev Disabil. 2016;54:381––90.
3. Durkin M. The epidemiology of developmental disabilities in
low-income countries. Ment Retard Dev Disabil Res Rev. 2002;8:
206–11.
4. Leonard H, Wen X. The epidemiology of mental retardation:
challenges and opportunities in the new millennium. Ment Retard
Dev Disabil Res Rev. 2002;8:117–34.
5. Raymond FL. X linked mental retardation: a clinical guide. J Med
Genet. 2006;43:193–200.
6. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S.
Prevalence of intellectual disability: a meta-analysis of population-
based studies. Res Dev Disabil. 2011;32:419–36. https://www.
sciencedirect.com/science/article/pii/S0891422210003082?via%
3Dihub.
7. Chelly J, Khelfaoui M, Francis F, et al. Genetics and pathophy-
siology of mental retardation. Eur J Hum Genet 2006;14:701–13.
https://doi.org/10.1038/sj.ejhg.5201595.
8. Vissers LELM, Gilissen C, Veltman JA. Genetic studies in
intellectual disability and related disorders. Nat Rev Genet.
2015;17:9–18. https://doi.org/10.1038/nrg3999.
9. Posada De La Paz M, Taruscio D, Groft SC. Rare diseases epi-
demiology: update and overview. Adv Exp Med Biol. 2017;1031.
10. Di KN, Disteche CM. Dosage compensation of the active X
chromosome in mammals. Nat Genet. 2006;38:47–53.
11. Zechner U, Wilda M, Kehrer-Sawatzki H, Vogel W, Fundele R,
Hameister H. A high density of X-linked genes for general cog-
nitive ability: a run-away process shaping human evolution?
Trends Genet. 2001;17:697–701.
12. Skuse DH. X-linked genes and mental functioning. Hum Mol
Genet. 2005;14:27–32.
13. Piton A, Redin C, Mandel JL. Erratum: XLID-causing mutations
and associated genes challenged in light of data from large-
scale human exome sequencing(S0002929713002826)(10.1016/j.
ajhg.2013.06.013). Am J Hum Genet. 2013;93:406.
14. Hu H, Haas SA, Chelly J, Van Esch H, Raynaud M, De Brouwer
APM, et al. X-exome sequencing of 405 unresolved families
identiﬁes seven novel intellectual disability genes. Mol Psy-
chiatry. 2016;21:133–48.
15. Muthusamy B, Selvan LDN, Nguyen TT, Manoj J, Stawiski EW,
Jaiswal BS, et al. Next-generation sequencing reveals novel
mutations in X-linked intellectual disability. Omi A J Integr Biol.
2017;21:295–303. https://doi.org/10.1089/omi.2017.0009.
16. Neri G, Schwartz CE, Lubs HA, Stevenson RE. X‐linked intel-
lectual disability update 2017. Am J Med Genet Part A.
2018;176A:1375–88. https://doi.org/10.1002/ajmg.a.38710.
17. Kreppel LK, Blomberg Ma, Hart GW. Dynamic glycosylation of
nuclear and cytosolic proteins. J Biol Chem. 1997;272:9308–15.
18. Lubas WA, Frank DW, Krause M, Hanover JA. O-Linked GlcNAc
transferase is a conserved nucleocytoplasmic protein containing
tetratricopeptide repeats. J Biol Chem. 1997;272:9316–24. http://
www.ncbi.nlm.nih.gov/pubmed/9083068.
19. Shaﬁ R, Iyer SPN, Ellies LG, O’Donnell N, Marek KW, Chui D,
et al. The O-GlcNAc transferase gene resides on the X chromo-
some and is essential for embryonic stem cell viability and mouse
ontogeny. Proc Natl Acad Sci USA. 2000;97:5735–9. http://www.
ncbi.nlm.nih.gov/pubmed/10801981.
20. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk
between O-GlcNAcylation and phosphorylation: roles in signaling,
transcription, and chronic disease. Annu Rev Biochem. 2011;
80:825–58. https://www.ncbi.nlm.nih.gov/pubmed/21391816.
21. Zhu Y, Liu TW, Cecioni S, Eskandari R, Zandberg WF, Vocadlo
DJ. O-GlcNAc occurs cotranslationally to stabilize nascent poly-
peptide chains. Nat Chem Biol. 2015;11:319–25. https://www.
ncbi.nlm.nih.gov/pubmed/25774941.
22. Wang YC, Peterson SE, Loring JF. Protein post-translational
modiﬁcations and regulation of pluripotency in human stem cells.
Cell Res. 2014;24:143–60. https://doi.org/10.1038/cr.2013.151.
23. Streubel G, Fitzpatrick DJ, Oliviero G, Scelfo A, Moran B, Das S,
et al. Fam60a deﬁnes a variant Sin3a‐Hdac complex in embryonic
stem cells required for self‐renewal. EMBO J. 2017;36:2216–32.
https://doi.org/10.15252/embj.201696307.
24. Krause M, Love DC, Ghosh S, Wang P, Yun S, Fukushige T, et al.
Nutrient-driven O-GlcNAcylation at promoters impacts genome-
wide RNA Pol II distribution. Front Endocrinol. 2018;9:521.
25. Slawson C, Copeland RJ, Hart GW. O-GlcNAc signaling: a
metabolic link between diabetes and cancer? Trends Biochem Sci.
2010;35:547–55.
26. Sakabe K, Hart GW. O-GlcNAc transferase regulates mitotic
chromatin dynamics. J Biol Chem. 2010;285:34460–8.
27. Dias WB, Hart GW. O-GlcNAc modiﬁcation in diabetes and
Alzheimer’s disease. Mol Biosyst. 2007;3:766. http://xlink.rsc.
org/?DOI=b704905f.
28. Zhu Y, Shan X, Yuzwa SA, Vocadlo DJ. The emerging
link between O-GlcNAc and Alzheimer disease. J Biol Chem.
2014;289:34472–81.
29. Willems AP, Gundogdu M, Kempers MJE, Giltay JC, Pfundt R,
Elferink M, et al. Mutations in N-acetylglucosamine (O-GlcNAc)
transferase in patients with X-linked intellectual disability. J Biol
Chem. 2017;292:12621–31. http://www.ncbi.nlm.nih.gov/pubmed/
28584052.
30. Vaidyanathan K, Niranjan T, Selvan N, Teo CF, May M,
Patel S, et al. Identiﬁcation and characterization of a missense
mutation in the O-linked ␤ - N-acetylglucosamine (O-GlcNAc)
transferase gene that segregates with X-linked intellectual dis-
ability. J Biol Chem. 2017;292:8948–63.
31. Selvan N, George S, Serajee FJ, Shaw M, Hobson L, Kalscheuer
V, et al. O-GlcNAc transferase missense mutations linked to X-
linked intellectual disability deregulate genes involved in cell fate
determination and signaling. J Biol Chem. 2018;293:10810–24.
32. Pravata VM, Muha V, Gundogdu M, Ferenbach AT, Kakade PS,
Vandadi V, et al. Catalytic deﬁciency of O-GlcNAc transferase
leads to X-linked intellectual disability. Proc Natl Acad Sci
USA. 2019;116:14961–70. http://www.ncbi.nlm.nih.gov/pubmed/
31296563.
33. Pravata VM, Gundogdu M, Bartual SG, Ferenbach AT, Stavridis
M, Õunap K, et al. A missense mutation in the catalytic domain
of O‐GlcNAc transferase links perturbations in protein O‐
GlcNAcylation to X‐linked intellectual disability. FEBS Lett.
2020. https://doi.org/10.1002/1873-3468.13640.
34. Iyer SPN, Hart GW. Roles of the tetratricopeptide repeat domain
in O-GlcNAc transferase targeting and protein substrate speciﬁ-
city. J Biol Chem. 2003;278:24608–16. http://www.ncbi.nlm.nih.
gov/pubmed/12724313.
35. Jínek M, Rehwinkel J, Lazarus BD, Izaurralde E, Hanover JA,
Conti E. The superhelical TPR-repeat domain of O-linked
GlcNAc transferase exhibits structural similarities to importin α.
Nat Struct Mol Biol. 2004;11:1001–7. https://doi.org/10.1038/
nsmb833.
36. Lazarus MB, Nam Y, Jiang J, Sliz P, Walker S. Structure of human
O-GlcNAc transferase and its complex with a peptide substrate.
Nature. 2011;469:564–7. https://doi.org/10.1038/nature09638.
V. M. Pravata et al.
37. Donnell NO, Zachara NE, Hart GW, Marth JD. Ogt-dependent X-
chromosome-linked protein glycosylation is a requisite modiﬁca-
tion in somatic cell function and embryo viability. Mol Cell Biol.
2004;24:1680–90.
38. Webster DM, Teo CF, Sun Y, Wloga D, Gay S, Klonowski KD,
et al. O-GlcNAc modiﬁcations regulate cell survival and epiboly
during zebraﬁsh development. BMC Dev Biol. 2009;9:28.
https://www.ncbi.nlm.nih.gov/pubmed/19383152.
39. Ingham PW. A gene that regulates the bithorax complex differen-
tially in larval and adult cells of Drosophila. Cell. 1984;37:815–23.
https://www.ncbi.nlm.nih.gov/pubmed/6430566.
40. Gambetta MC, Oktaba K, Muller J, Müller J. Essential role of the
glycosyltransferase Sxc/Ogt in polycomb repression. Science.
2009;325:93–6. http://www.ncbi.nlm.nih.gov/pubmed/19478141.
41. Sinclair DAR, Syrzycka M, Macauley MS, Rastgardani T, Koml-
jenovic I, Vocadlo DJ, et al. Drosophila O-GlcNAc transferase
(OGT) is encoded by the Polycomb group (PcG) gene, super sex
combs (sxc). Proc Natl Acad Sci USA. 2009;106:13427–32.
http://www.ncbi.nlm.nih.gov/pubmed/19666537.
42. Capotosti F, Guernier S, Lammers F, Waridel P, Cai Y, Jin J, et al.
O -GlcNAc transferase catalyzes site-speciﬁc proteolysis of HCF-1.
Cell. 2010;144:376–88. https://doi.org/10.1016/j.cell.2010.12.030.
43. Lazarus MB, Jiang J, Kapuria V, Bhuiyan T, Janetzko J, Zandberg
WF, et al. HCF-1 is cleaved in the active site of O-GlcNAc
transferase. Science. 2013;342:1235–9. http://www.ncbi.nlm.nih.
gov/pubmed/24311690.
44. Bouazzi H, Lesca G, Trujillo C, Alwasiyah MK, Munnich A.
Nonsyndromic X-linked intellectual deﬁciency in three brothers with
a novel MED12 missense mutation [c.5922G>T (p.Glu1974His)].
Clin Case Rep. 2015;3:604–9. https://doi.org/10.1002/ccr3.301.
45. Niranjan TS, Skinner C, May M, Turner T, Rose R, Stevenson R,
et al. Affected kindred analysis of human X chromosome exomes
to identify novel X-linked intellectual disability genes. PLoS One.
2015;10:1–22. https://doi.org/10.1371/journal.pone.0116454.
46. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den
Dunnen JT. LOVD v.2.0: the next generation in gene variant
databases. Hum Mutat. 2011;32:557–63.
47. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan
D, et al. DECIPHER: database of chromosomal imbalance and
phenotype in humans using ensembl resources. Am J Hum Genet.
2009;84:524–33.
48. Akimoto Y, Comer FI, Cole RN, Kudo A, Kawakami H, Hirano H,
et al. Localization of the O-GlcNAc transferase and O-GlcNAc-
modiﬁed proteins in rat cerebellar cortex. Brain Res.
2003;966:194–205. http://www.ncbi.nlm.nih.gov/pubmed/12618343.
49. Vosseller K, Trinidad JC, Chalkley RJ, Specht CG, Thalhammer
A, Lynn AJ, et al. O-linked N-acetylglucosamine proteomics of
postsynaptic density preparations using lectin weak afﬁnity chro-
matography and mass spectrometry. Mol Cell Proteom.
2006;5:923–34. https://www.ncbi.nlm.nih.gov/pubmed/16452088.
50. Teo CF, Ingale S, Wolfert MA, Elsayed GA, Nöt LG, Chatham
JC, et al. Glycopeptide-speciﬁc monoclonal antibodies suggest
new roles for O-GlcNAc. Nat Chem Biol. 2010;6:338–43.
51. Ma J, Hart GW. Analysis of protein phosphorylation by mass
spectrometry. Curr Protoc Protein Sci. 2017;35:256–64.
52. Mariappa D, Selvan N, Borodkin V, Alonso J, Andrew T,
Shepherd C, et al. A mutant O-GlcNAcase as a probe to reveal
global dynamics of the Drosophila O-GlcNAc developmental
proteome. Biochem J. 2015;470:255–62.
53. Selvan N, Williamson R, Mariappa D, Campbell DG, Gourlay R,
Ferenbach AT, et al. A mutant O-GlcNAcase enriches Drosophila
developmental regulators. Nat Chem Biol. 2017;13:882–7.
54. Zhang Z, Tan EP, VandenHull NJ, Peterson KR, Slawson C. O-
GlcNAcase expression is sensitive to changes in O-GlcNAc
homeostasis. Front Endocrinol. 2014;5:206 http://www.ncbi.nlm.
nih.gov/pubmed/25520704.
55. Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de
Leeuw CA, et al. Genome-wide association meta-analysis in 269,
867 individuals identiﬁes new genetic and functional links to
intelligence. Nat Genet. 2018;50:912–9. http://www.nature.com/a
rticles/s41588-018-0152-6.
56. Olivier-Van Stichelen S, Wang P, Comly M, Love DC, Hanover
JA. Nutrient-driven O-linked N-acetylglucosamine (O-GlcNAc)
cycling impacts neurodevelopmental timing and metabolism. J
Biol Chem. 2017;292:6076–85. https://doi.org/10.1074/jbc.M116.
774042.
57. Huang L, Jolly LA, Willis-Owen S, Gardner A, Kumar R, Douglas E,
et al. A noncoding, regulatory mutation implicates HCFC1 in non-
syndromic intellectual disability. Am J Hum Genet. 2012;91:694–702.
https://www.ncbi.nlm.nih.gov/pubmed/23000143.
58. Jaworski A, Smith CL, Burden SJ. GA-binding protein is dis-
pensable for neuromuscular synapse formation and synapse-
speciﬁc gene expression. Mol Cell Biol. 2007;27:5040–6.
http://www.ncbi.nlm.nih.gov/pubmed/17485447.
59. Gundogdu M, Llabrés S, Gorelik A, Ferenbach AT, Zachariae
U, van Aalten DMF. The O-GlcNAc transferase intellectual
disability mutation L254F distorts the TPR helix. Cell Chem
Biol. 2018;25:513–518.e4.
60. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear O-
GlcNAc transferase. J Biol Chem. 1999;274:32015–22.
61. Lamb JR, Michaud WA, Sikorski RS, Hieter PA. Cdc16p, Cdc23p
and Cdc27p form a complex essential for mitosis. Embo J. 1994;
13:4321–8.
62. Péanne R, de Lonlay P, Foulquier F, Kornak U, Lefeber DJ,
Morava E, et al. Congenital disorders of glycosylation (CDG):
Quo vadis? Eur J Med Genet. 2018;61:643–63.
63. Brasil S, Pascoal C, Francisco R, Marques-da-Silva D, Andreotti
G, Videira PA, et al. CDG therapies: from bench to bedside. Int J
Mol Sci. 2018;19:E1304.
64. Koch J, Mayr JA, Alhaddad B, Rauscher C, Bierau J, Kovacs-
Nagy R, et al. CAD mutations and uridine-responsive epileptic
encephalopathy. Brain. 2017;140:279–86.
65. Park JH, Hogrebe M, Fobker M, Brackmann R, Fiedler B,
Reunert J, et al. SLC39A8 deﬁciency: biochemical correction
and major clinical improvement by manganese therapy. Genet
Med. 2017;20:259.
66. Morelle W, Potelle S, Witters P, Wong S, Climer L, Lupashin V,
et al. Galactose supplementation in patients with TMEM165-CDG
rescues the glycosylation defects. J Clin Endocrinol Metab.
2017;102:1375–86. https://doi.org/10.1210/jc.2016-3443.
67. Love DC, Hanover JA. The hexosamine signaling pathway:
deciphering the “O-GlcNAc code.”. Sci Signal. 2005;2005:
re13–re13. https://doi.org/10.1126/stke.3122005re13.
68. Dorfmueller HC, Borodkin VS, Blair DE, Pathak S, Navratilova I,
Van Aalten DMF. Substrate and product analogues as human O-
GlcNAc transferase inhibitors. Amino Acids. 2010;40:781–92.
69. Dorfmueller HC, Borodkin VS, Schimpl M, van Aalten
DMF. GlcNAcstatins are nanomolar inhibitors of human O-
GlcNAcase inducing cellular hyper-O-GlcNAcylation. Biochem
J. 2009;420:221–7.
70. Macauley MS, Vocadlo DJ. Increasing O-GlcNAc levels: an
overview of small-molecule inhibitors of O-GlcNAcase. Biochim
Biophys Acta. 2010;1800:107–21. https://www.sciencedirect.com/
science/article/pii/S0304416509002190?via%3Dihub.
71. Vaidyanathan K, Durning S, Wells L. Functional O-GlcNAc
modiﬁcations: implications in molecular regulation and patho-
physiology. Crit Rev Biochem Mol Biol. 2014;49:140–63.
http://www.ncbi.nlm.nih.gov/pubmed/24524620.
An intellectual disability syndrome with single-nucleotide variants in O-GlcNAc transferase
